Applied DNA Sciences and Kudo Biotechnology announced their entry into a joint development agreement to integrate Applied DNA’s Linea IVT platform into Kudo Bio’s commercial mRNA manufacturing workflows. Under the terms of the JDA, the Companies will seek to optimize mRNA quality, yields, and mitigation of contamination by double-stranded RNA in an integrated workflow at manufacturing scale and establish a global co-marketing relationship. Upon completion of the JDA, the Companies plan to negotiate agreements to enable the commercial launch of the joint workflow in the second half of calendar 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APDN: